Current Cardiology Reports

, Volume 3, Issue 6, pp 459–466 | Cite as

Are drugs and catheter ablation effective for treating ventricular arrhythmias in populations that cannot afford implantable cardioverter defibrillators?

  • Kewal K. Talwar
  • Nitish Naik
  • Rajnish Juneja
Article
  • 33 Downloads

Abstract

Despite recent advances, ventricular arrhythmias continue to pose a therapeutic challenge, especially to the clinician in the developing world. Although the implantable cardioverter defibrillator (ICD) has improved survival in both primary and secondary prevention trials, it still remains a costly modality for the developing world. Even though certain subgroups stand to benefit unequivocally in survival from the ICD, there are others in whom this therapy may not offer a survival benefit over empiric antiarrhythmic drug therapy with amiodarone. The utility of optimized drug therapy (including either amiodarone or sotalol, b-blockers, and angiotensin-converting enzyme inhibitors) needs to be compared with the ICD in a randomized manner in these lower-risk patients with ventricular arrhythmias. The role of conventional catheter ablation techniques is mostly adjunctive to drugs and ICDs, although the newer mapping and ablation techniques may offer greater promise in the future.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Myerburg RJ, Kessler KM, Castellanos A: Sudden cardiac death: epidemiology, transient risk and intervention assessment. Ann Intern Med 1993, 119:1187–1197.PubMedGoogle Scholar
  2. 2.
    Murray CJL, Lopez AD: Global comparative assessments in the health sector. Geneva, Switzerland. World Health Organization, 1994.Google Scholar
  3. 3.
    Reddy KS, Yusuf S: Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998, 97:596–601.PubMedGoogle Scholar
  4. 4.
    Gilkson M, Friedman PA: The implantable cardioverter defibrillator. Lancet 2001, 357:1107–1117.CrossRefGoogle Scholar
  5. 5.
    Higgins SL: Impact of the multicenter automatic defibrillator implantation trial on implantable cardioverter defibrillator indication trends. Am J Cardiol 1999, 83:79D-82D.PubMedCrossRefGoogle Scholar
  6. 6.
    Nasir N, Swarna US, Boachene KA, et al.: Therapy of sustained ventricular arrhythmias with amiodarone: prediction of efficacy with serial electrophysiologic studies. J Cardiovasc Pharmacol Ther 1996, 1:123–133.PubMedGoogle Scholar
  7. 7.
    The AVID Investigators: A comparison of antiarrhythmic drug therapy with implantable-cardioverter defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997, 337:1576–1583.CrossRefGoogle Scholar
  8. 8.
    Connolly SJ, Gent M, Roberts RS, et al., for the CIDS Investigators: Canadian Implantable Defibrillator Study (CIDS): a randomized trial of the implantable cardioverter defibrillator against amiodarone. Circulation 2000, 101:1297–1302.PubMedGoogle Scholar
  9. 9.
    Kuck KH, Cappato R, Siebels J, Ruppel R, for the CASH Investigators: Randomized comparison of antiarrhythmic drug therapy with implantable defibrillators in patients resuscitated from cardiac arrest. The Cardiac Arrest Study (bdCASH). Circulation 2000, 102:748–754.PubMedGoogle Scholar
  10. 10.
    O’Brien B, Connolly SJ, Goeree R, et al. for the CIDS Investigators: Cost-effectiveness of the Implantable Cardioverter Defibrillator: results from the Canadian Implantable Defibrillator Study (bdCIDS). Circulation 2001, 103:1416–1421. An excellent study analyzing the cost-effectiveness of the ICD using three different benefit curves.PubMedGoogle Scholar
  11. 11.
    Sarter BH, Finkle JK, Gerszten RE, Buxton AE: What is the risk of sudden cardiac death in patients presenting with hemodynamically stable sustained ventricular tachycardia after myocardial infarction? J Am Coll Cardiol 1996, 28:122–129.PubMedCrossRefGoogle Scholar
  12. 12.
    Brugada P, Talajic M, Smeets J, etal.: The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction. Eur Heart J 1989, 10:747–752.PubMedGoogle Scholar
  13. 13.
    Maury P, Zimmermann M, Metzger J, et al.: Amiodarone therapy for sustained ventricular tachycardia after myocardial infarction: long-term follow-up, risk assessment and predictive value of programmed ventricular stimulation. Int J Cardiol 2000, 76:199–210.PubMedCrossRefGoogle Scholar
  14. 14.
    Domanski MJ, Sakseena S, Epstein AE, et al., for the AVID Investigators: Relative effectiveness of the implantable cardioverter-defibrillator and antiarrhythmic drugs in patients with varying degrees of left ventricular dysfunction who have survived malignant ventricular arrhythmias. J Am Coll Cardiol 1999, 34:1090–1095. Subanalysis from the AVID trial demonstrating differences in ICD benefit stratifiable according to left ventricular function.PubMedCrossRefGoogle Scholar
  15. 15.
    Farre J, Cabrera JA, Romero J, Rubio J: Therapeutic decision tree for patients with sustained ventricular tachyarrhythmias or aborted sudden death: a critical review of the Antiarrhythmics versus Implantable Defibrillator trial and the Canadian Implantable Defibrillator study. Am J Cardiol 2000, 86:44K-51K. A concise critical review of the two randomized secondary prevention ICD trials.PubMedCrossRefGoogle Scholar
  16. 16.
    Sheldon R, Connolly S, Krahn A, et al. on behalf of the CIDS Investigators: Identification of patients most likely to benefit from implantable cardioverter-defibrillator therapy. Canadian Implantable Defibrillator Study. Circulation 2000, 101:1660–1664. Subanalysis from CIDS demonstrating utility of a risk score in identifying patients who may benefit from the ICD.PubMedGoogle Scholar
  17. 17.
    Carusco AC, Marcus FI, Hahn EA, et al., and the ESVEM Investigators: Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Circulation 1997, 96:1888–1892.Google Scholar
  18. 18.
    Bocker D, Block M, Isbruch F, et al.: Benefits of treatment with implantable cardioverter-defibrillators in patients with stable ventricular tachycardia without cardiac arrest. Br Heart J 1995, 73:158–163.PubMedGoogle Scholar
  19. 19.
    Raitt MH, Renfroe EG, Epstein AE, et al., for the AVID Investigators: ""Stable" ventricular tachycardia is not a benign rhythm: insights from the Antiarrhythmics Versus Implantable Defibrillators (AVID) registry. Circulation 2001, 103:244–252.PubMedGoogle Scholar
  20. 20.
    Hallstrom AP, McAnulty JH, Wilkoff BL, et al., for the Antiarrhythmics Versus Implantable Defibrillator (AVID) Trial Investigators: Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibrillators may not offer benefit. J Am Coll Cardiol 2001, 37:1093–1099.PubMedCrossRefGoogle Scholar
  21. 21.
    Mason JW, for the Electrophysiologic Study versus Electrocardiographic Monitoring Investigators: A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993, 329:52–58.Google Scholar
  22. 22.
    Amiodarone versus Sotalol Study Group: Multicenter randomized trial of sotalol versus amiodarone for chronic malignant ventricular arrhythmias. Eur Heart J 1989, 10:685–694.Google Scholar
  23. 23.
    Kovoor P, Eipper V, Byth K, et al.: Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. Eur Heart J 1999, 20:364–374.PubMedCrossRefGoogle Scholar
  24. 24.
    Hjalmarson A: Effects of beta-blockade on sudden cardiac death during acute myocardial infarction and the post infarction period. Am J Cardiol 1997, 80(Suppl):35J-39J.PubMedCrossRefGoogle Scholar
  25. 25.
    Gottlieb SS, McCarter RJ, Vogel RA: Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998, 339:489–499.PubMedCrossRefGoogle Scholar
  26. 26.
    Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation Study (TRACE) group: A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995, 333:1670–1676.PubMedCrossRefGoogle Scholar
  27. 27.
    De Sutter J, Tavernier R, De Buyzere M, et al.: Lipid lowering drugs and recurrences of life-threatening ventricular arrhythmias in high-risk patients. J Am Coll Cardiol 2000, 36:766–772. An observational study documenting antiarrhythmic benefits of lipid lowering agents in patients with serious ventricular arrhythmias.PubMedCrossRefGoogle Scholar
  28. 28.
    Morady F, Harvey M, Kalbfleisch SJ, et al.: Radiofrequency catheter ablation of ventricular tachycardia in patients with coronary artery disease. Circulation 1993, 87:363–372.PubMedGoogle Scholar
  29. 29.
    Kim YH, Sosa-Suarez G, Traxton TG, et al.: Treatment of ventricular tachycardia by transcatheter ablation in patients with ischemic heart disease. Circulation 1994, 89:1094–1102.PubMedGoogle Scholar
  30. 30.
    Gonska BD, Cao K, Scehanmann A, et al.: Catheter ablation of ventricular tachycardia in 136 patients with coronary artery disease: results and long-term follow-up. J Am Coll Cardiol 1994, 24:1506–1514.PubMedCrossRefGoogle Scholar
  31. 31.
    Stevenson WG, Friedman PL, Kocovic D, et al.: Radiofrequency catheter ablation of ventricular tachycardia after myocardial infarction. Circulation 1998, 98:308–314.PubMedGoogle Scholar
  32. 32.
    Rothman SA, Hsia HH, Cossu SF, et al.: Radiofrequency catheter ablation of post infarction ventricular tachycardia: long-term success and the significance of inducible nonclinical arrhythmias. Circulation 1997, 96:3499–3508.PubMedGoogle Scholar
  33. 33.
    O’Callaghan PA, Poloniecki J, Sosa-Suarez G, et al.: Long-term clinical outcome of patients with prior myocardial infarction after palliative radiofrequency catheter ablation for frequent ventricular tachycardia. Am J Cardiol 2001, 87:975–979.PubMedCrossRefGoogle Scholar
  34. 34.
    Calkins H, Epstein A, Packer D, et al.: Catheter ablation of ventricular tachycardia in patients with structural heart disease using cooled radiofrequency energy: results of a prospective multicenter study. Cooled RF Multicenter investigators group. J Am Coll Cardiol 2000, 35:1905–1914.PubMedCrossRefGoogle Scholar
  35. 35.
    Greenspon AJ, Hsu SS, Datorre S: Successful radiofrequency catheter ablation of sustained ventricular tachycardial post myocardial infarction in man guided by a multielectrote ""basket"" catheter. J Cardiovasc Electrophysiol 1997, 8:565–570.PubMedCrossRefGoogle Scholar
  36. 36.
    Marchlinski FE, Callans DJ, Gottlieb CD, Zado E: Linear ablation lesions for control of unmappable ventricular tachycardia in patients with ischemic and nonischemic cardiomyopathy. Circulation 2000, 101:1288–1296. A descriptive study regarding utility of CATO in mapping and ablating unstable ischemic VTs.PubMedGoogle Scholar
  37. 37.
    Strickberger SA, Knight BP, Michaud GF, et al.: Mapping and ablation of ventricular tachycardia guided by virtual electrograms using a noncontact, computerized mapping system. J Am Coll Cardiol 2000, 35:414–421.PubMedCrossRefGoogle Scholar
  38. 38.
    Moss AJ, Hall WJ, Cannom DS, et al.: Improved survival with an implanted defibrillator in patients with coronary artery disease at high risk of ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation trial Investigators. N Engl J Med 1996, 335:1933–1940.PubMedCrossRefGoogle Scholar
  39. 39.
    Buxton AE, Lee KL, Fisher JD, et al.: A randomized study of the prevention of sudden death in patients with coronary artery disease: Multicenter Unstained Tachycardia Trial Investigators. N Engl J Med 1999, 341:1882–1890.PubMedCrossRefGoogle Scholar
  40. 40.
    Raviele A, Bongiorni MG, Brignole M, et al.: Which strategy is ""best"" after myocardial infarction? The Beta-Blocker strategy plus Implantable Cardioverter Defibrillator trial: rationale and study design. Am J Cardiol 1999, 83:104D-111D.PubMedCrossRefGoogle Scholar
  41. 41.
    Zipes DP: Implantable cardioverter defibrillator: a Volkswagen or a Rolls Royce. How much will we pay to save a life? Circulation 2001, 103:1372–1374. An excellent editorial highlighting the need for less expensive and simpler ICDs in some patients.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Kewal K. Talwar
    • 1
  • Nitish Naik
    • 1
  • Rajnish Juneja
    • 1
  1. 1.Department of Cardiology, Cardiothoracic CenterAll India Institute of Medical SciencesNew DelhiIndia

Personalised recommendations